Ikarian Capital’s RAPT Therapeutics RAPT Stock Holding History

Ikarian Capital’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-665,271	Closed	-$22.5M	–	204
2025 Q4	$22.5M	Buy	665,271 +50,271	+8%	+$1.56M	1.76%	13
2025 Q3	$15.9M	Buy	+615,000	New	+$8.05M	1.6%	12
2024 Q4	–	Sell	-19,328	Closed	-$311K	–	199
2024 Q3	$311K	Hold	19,328	–	–	0.04%	127
2024 Q2	$472K	Hold	19,328	–	–	0.08%	95
2024 Q1	$1.39M	Buy	+19,328	New	+$2.69M	0.15%	97

Ikarian Capital's RAPT Position: Q1 2026 in Review

Ikarian Capital sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 665,271 shares — an estimated $22.5M sold.

Ikarian Capital first reported a position in RAPT in Q1 2024 and held it in 5 quarters. The position peaked at $22.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Ikarian Capital reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Ikarian Capital sold 665,271 RAPT Therapeutics shares in Q1 2026, an estimated $22.5M.
Ikarian Capital first reported a position in RAPT Therapeutics in Q1 2024 and held it in 5 quarters.
Ikarian Capital's RAPT Therapeutics position peaked at $22.5M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.